PT  - JOURNAL ARTICLE
AU  - Palmos, Alish B.
AU  - Millischer, Vincent
AU  - Menon, David K.
AU  - Nicholson, Timothy R.
AU  - Taams, Leonie
AU  - Michael, Benedict
AU - COVID Clinical Neuroscience Study Consortium
AU  - Hübel, Christopher
AU  - Breen, Gerome
TI  - Proteome-wide Mendelian randomization identifies causal links between blood proteins and severe COVID-19
AID  - 10.1101/2021.03.09.21253206
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.09.21253206
4099  - http://medrxiv.org/content/early/2021/03/11/2021.03.09.21253206.short
4100  - http://medrxiv.org/content/early/2021/03/11/2021.03.09.21253206.full
AB  - The COVID-19 pandemic death toll now surpasses two million individuals and there is a need for early identification of individuals at increased risk of mortality. Host genetic variation partially drives the immune and biochemical responses to COVID-19 that lead to risk of mortality. We identify and prioritise blood proteins and biomarkers that may indicate increased risk for severe COVID-19, via a proteome Mendelian randomization approach by collecting genome-wide association study (GWAS) summary statistics for >4,000 blood proteins. After multiple testing correction, troponin I3, cardiac type (TNNI3) had the strongest effect (odds ratio (O.R.) of 6.86 per standard deviation increase in protein level), with proteinase 3 (PRTN3) (O.R.=2.48), major histocompatibility complex, class II, DQ alpha 2 (HLA-DQA2) (O.R.=2.29), the C4A-C4B heterodimer (O.R.=1.76) and low-density lipoprotein receptor-related protein associated protein 1 (LRPAP1) (O.R.=1.73) also being associated with higher odds of severe COVID-19. Conversely, major histocompatibility complex class I polypeptide-related sequence A (MHC1A) (O.R.=0.6) and natural cytotoxicity triggering receptor 3 (NCR3) (O.R.=0.46) were associated with lower odds. These proteins are involved in heart muscle contraction, natural killer and antigen presenting cells, and the major histocompatibility complex. Based on these findings, it may be possible to better predict which patients may develop severe COVID-19 and to design better treatments targeting the implicated mechanisms.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCOVID-19 Clinical Neuroscience Study is funded by the Medical Research Council.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB/oversight body is exempted. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and software is publicly available via original sources.C4Acomplement C4A (Rodgers blood group)C4Bcomplement C4B (Chido blood group)CREB3L4cAMP responsive element binding protein 3 like 4COVID-19coronavirus disease 2019DEFB119beta-defensin 119GWASgenome-wide association studyHLA-DQA2major histocompatibility complex (MHC), class II, DQ alpha 2LRPAP1low-density lipoprotein (LDL) receptor-related protein associated protein 1MICAMHC class I polypeptide-related sequence ANCR3natural cytotoxicity triggering receptor 3ORodds ratioPRTN3proteinase 3TNNI3troponin I3, cardiac typeSARS-CoV-2severe acute respiratory syndrome coronavirus 2SEstandard errorSNPsingle nucleotide polymorphism